Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial
- PMID: 26341710
- PMCID: PMC4587355
- DOI: 10.1016/j.ygyno.2015.08.022
Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial
Abstract
Background: Few studies have analyzed relationships between risk factors for endometrial cancer, especially with regard to aggressive (non-endometrioid) histologic subtypes, and prognosis. We examined these relationships in the prospective NRG Oncology/Gynecologic Oncology Group 210 trial.
Methods: Prior to surgery, participants completed a questionnaire assessing risk factors for gynecologic cancers. Pathology data were derived from clinical reports and central review. We used the Fine and Gray subdistribution hazards model to estimate subhazard ratios (HRs) and 95% confidence intervals (CIs) for associations between etiologic factors and cause-specific subhazards in the presence of competing risks. These models were stratified by tumor subtype and adjusted for stage and socioeconomic status indicators.
Results: Median follow-up was 60months after enrollment (range: 1day-118months). Among 4609 participants, a total of 854 deaths occurred, of which, 582 deaths were attributed to endometrial carcinoma. Among low-grade endometrioid cases, endometrial carcinoma-specific subhazards were significantly associated with age at diagnosis (HR=1.04, 95% CI=1.01-1.06 per year, P-trend) and BMI (class II obesity vs. normal BMI: HR=2.29, 95% CI=1.06-4.98, P-trend=0.01). Among high-grade endometrioid cases, endometrial carcinoma-specific subhazards were associated with age at diagnosis (HR=1.05, 95% CI=1.02-1.07 per year, P-trend<0.001). Among non-endometrioid cases, endometrial carcinoma-specific subhazards were associated with parity relative to nulliparity among serous (HR=0.55, 95% CI=0.36-0.82) and carcinosarcoma cases (HR=2.01, 95% CI=1.00-4.05).
Discussion: Several endometrial carcinoma risk factors are associated with prognosis, which occurs in a tumor-subtype specific context. If confirmed, these results would suggest that factors beyond histopathologic features and stage are related to prognosis. ClinicalTrials.gov Identifier: NCT00340808.
Keywords: Endometrial cancer; Etiologic factors; GOG; NRG; Prognosis.
Published by Elsevier Inc.
Similar articles
-
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.J Natl Cancer Inst. 2017 Mar 1;109(3):1-10. doi: 10.1093/jnci/djw251. J Natl Cancer Inst. 2017. PMID: 28376204 Free PMC article.
-
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.Gynecol Oncol. 2013 May;129(2):277-84. doi: 10.1016/j.ygyno.2013.02.023. Epub 2013 Feb 26. Gynecol Oncol. 2013. PMID: 23485770 Free PMC article.
-
Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.Int J Cancer. 2018 Mar 15;142(6):1102-1115. doi: 10.1002/ijc.31127. Epub 2017 Nov 6. Int J Cancer. 2018. PMID: 29063589 Free PMC article.
-
Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.J Natl Cancer Inst. 2015 Jun 18;107(9):djv158. doi: 10.1093/jnci/djv158. Print 2015 Sep. J Natl Cancer Inst. 2015. PMID: 26089540 Free PMC article. Clinical Trial.
-
Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.Gynecol Oncol. 2024 Mar;182:99-107. doi: 10.1016/j.ygyno.2024.01.018. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262245 Free PMC article.
Cited by
-
Plasma omega-3 polyunsaturated fatty acids and recurrence of endometrial cancer.BMC Cancer. 2020 Jun 20;20(1):576. doi: 10.1186/s12885-020-07035-5. BMC Cancer. 2020. PMID: 32563240 Free PMC article.
-
Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis.BMC Cancer. 2022 Apr 20;22(1):427. doi: 10.1186/s12885-022-09510-7. BMC Cancer. 2022. PMID: 35439978 Free PMC article.
-
Role of miR‑181a‑5p in cancer (Review).Int J Oncol. 2023 Oct;63(4):108. doi: 10.3892/ijo.2023.5556. Epub 2023 Aug 4. Int J Oncol. 2023. PMID: 37539738 Free PMC article. Review.
-
Machine learning-based neddylation landscape indicates different prognosis and immune microenvironment in endometrial cancer.Front Oncol. 2023 Feb 22;13:1084523. doi: 10.3389/fonc.2023.1084523. eCollection 2023. Front Oncol. 2023. PMID: 36910623 Free PMC article.
-
Imiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.Pharm Res. 2016 Sep;33(9):2209-17. doi: 10.1007/s11095-016-1957-6. Epub 2016 May 31. Pharm Res. 2016. PMID: 27245465 Free PMC article.
References
-
- Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S105–43. - PubMed
-
- Anderson B, Connor JP, Andrews JI, et al. Obesity and prognosis in endometrial cancer. Am J Obstet Gynecol. 1996;174(4):1171–8. discussion 1178–9. - PubMed
-
- Studzijnski Z, Zajewski W. Factors affecting the survival of 121 patients treated for endometrial carcinoma at a Polish hospital. Arch Gynecol Obstet. 2003;267(3):145–7. - PubMed
-
- Everett E, Tamimi H, Greer B, et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2003;90(1):150–7. - PubMed
-
- Kodama J, Seki N, Ojima Y, et al. Correlation of presenting symptoms and patient characteristics with endometrial cancer prognosis in Japanese women. Int J Gynaecol Obstet. 2005;91(2):151–6. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical